Developments Lineage presents additional interim data with OpRegen in dry AMD with GA Lineage Cell Therapeutics (NYSE American, TASE:LCTX) presented new positive interim results from its ongoing, 24-patient Phase 1/2a clinical study of its lead product candidate, OpRegen, for the treatment of dry age... March 23, 2021